 |
 |
 |
 |
 |
 |
 |
Member Information
Philip R. Johnson, M.D.
Professor of Pediatrics
Chief Scientific Officer
Children's Hospital of Philadelphia
Office Phone: 267-426-0351
Office Fax: 267-426-0363
Email: johnsonphi@chop.edu
Website(s): http://stokes.chop.edu/programs/johnsonlab
Education: M.D. 1980, University of North Carolina - Chapel Hill
Keywords: HIV; SIV; Vaccines; Gene transfer; AAV vectors
Research and/or Clinical interests:
HIV vaccine development
Summary:
Our laboratory has 2 major research themes. One focus area is vaccine development, especially for HIV. The laboratory has over 18 years of experience in the development of viral vectors for the delivery of vaccine antigens and the use of animal models to evaluate vaccine strategies. One of our lead vaccine candidates is now in phase I/II human trials in Europe, India , and Africa . The laboratory continues to evaluate new strategies for HIV vaccines.
The other major research theme is the development of recombinant adeno-associated virus (rAAV) as a vector for gene therapy. The laboratory has made seminal contributions in this field over the last 10 years, particularly in the area of vector production. The methods invented by the laboratory are now used to produce clinical grade vector that is being used in gene therapy trials several centers in the United States . The laboratory continues to seek novel uses for rAAV vectors in the treatment of human and animal diseases.
Representative Publications:
Lewis AD, Chen R, Montefiori DC, Johnson PR, and Clark KR. Generation of serum neutralizing activity against HIV-1 by antibody gene transfer. J Virol 76:8769-8775, 2002.
Schnepp BC , Klemanski DL, Pacak CA , Clark KR, and Johnson PR. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol. 77: 3495-350, 2003.
Haigwood NL, Montefiori DC, Sutton WF, McClure J, Watson AJ, Voss G, Hirsch VM, Richardson BA, Letvin NL, Hu SL, Johnson PR. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol. 78:5983-95, 2004.
Johnson PR, Schnepp BC, Connell MJ, Rohne D, Robinson S, Krivulka GR, Lord CI, Zinn R, Montefiori DC, Letvin NL, and Clark KR. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol. 79:955-65, 2005.
Chen C-L, Jensen RL, Schnepp BC, Connell MJ, Shell R, Sferra TJ, Bartlett JS, Clark KR, and Johnson PR. Molecular characterization of adeno-associated viruses in children. J Virol. 79:14781-92, 2005.
